The new facility adds capacity for the storage and handling of clinical trial supply materials at controlled room temperatures between 15 - 25 degrees Celsius.
$2.2 million expansion brings the site’s footprint to 31,000 sq.-ft., creating space for an additional 35 new freezers for ultra-low temperature storage.
To increase the site’s footprint by nearly 20% to 31,000 square feet, and allow the installation of 35 new freezers for ultra-low temperature (ULT) storage.
30,900-sq.-ft. facility in Princeton, NJ houses 16 suites for cGMP product production, and labs for analytical, quality control and microbiology testing.
Acquires facility in Oxfordshire and will invest up to $160 million to complete and equip it with state-of-the-art capabilities for biologics and vaccines.
Expansion in large-scale isolator units at Malvern and Dartford, UK facilities to provide advanced containment capabilities for highly potent drug compounds.
Autologous cell therapy for the treatment of ALS and PMS will be manufactured at Catalent’s 32,000 sq.-ft. cell therapy manufacturing facility in Houston.
The 24,000-sq.-ft. facility was established to support integrated development, clinical packaging, and distribution solutions for Phase 1-3 clinical studies.